PUBLISHER: DelveInsight | PRODUCT CODE: 1128285
PUBLISHER: DelveInsight | PRODUCT CODE: 1128285
"JAKAFI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about JAKAFI for Polycythemia Vera in the 7MM. A detailed picture of the JAKAFI for Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the JAKAFI for Polycythemia Vera. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JAKAFI market forecast, analysis for Polycythemia Vera in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Polycythemia Vera.
Jakafi is a kinase inhibitor developed by Incyte Corporationand and Novartis, designated for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis, post-polycythemia Vera (PV) myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. This drug is also approved for adult patients of PV who have had a poor response to hydroxyurea.
Polycythemia Vera is myeloproliferative neoplasms (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. Jakafi is a kinase inhibitor that specifically inhibits JAK1 and JAK2, which mediate the signaling of several cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves the recruitment of transcription factor STATs (signal transducers and activators of transcription) to cytokine receptors. It activates and subsequent localization of STATs to the nucleus leading to modulation of gene expression.
The recommended starting dose of Jakafi in PV is 10 mg given orally twice daily. There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and <100,000/mm3. The maximum recommended starting dose in these patients is 5 mg twice daily, and the patients must be titrated cautiously.
Jakafi is also approved for treating steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Some trials of the ruxolitinib are still ongoing in Phase III and Phase II clinical trials for the treatment of PV.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
JAKAFI Analytical Perspective by DelveInsight
This report provides a detailed market assessment of JAKAFI in Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.
The report provides the clinical trials information of JAKAFI for Polycythemia Vera covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions